Silo Pharma, Inc. — Director's Dealing 2025

Nov 20, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2025-11-18

Reporting Person: Weisblum Eric (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-18	Common Stock	P	7500	$0.4033	Acquired	205432	Direct
2025-11-19	Common Stock	P	4500	$0.4050	Acquired	209932	Direct

Footnotes

F1: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 18, 2025 at prices ranging from $0.4000 to $0.4050. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F2: This price reflects the weighted average price at which these shares were purchased. The shares were purchased in multiple transactions on November 19, 2025 at prices ranging from $0.3975 to $0.4100. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.